PI3K Inhibitors for HR+ Metastatic Breast Cancer

Panelists Adam M. Brufsky, MD, PhD; José Baselga, MD, PhD; Carlos L. Arteaga, MD; Debu Tripathy, MD; and Denise A. Yardley, MD, discuss the potential for use of PI3K inhibitors buparlisib, alpelisib, and taselisib and their anticipation of data coming in the near future for breast cancer.

• فئة